CRI's new website that seeks to engage, educate, and empower patients and their loved ones to learn more about cancer immunotherapy as a treatment option across numerous tumor types.
Cancer patients, donors, scientists, and other supporters all stand behind the Cancer Research Institute. Read their stories and learn about what motivates each of us to keep fighting against cancer.
Join us on June 25, 2016, for a one-day, multi-distance “Answer to Cancer” cycling event throughout New York's Lower Hudson Valley and sponsored by Bristol-Myers Squibb.
We gratefully accept donations made in memory or in honor of a loved one. Your gift will be acknowledged to whomever you specify.
Numerous challenges can slow progress in finding new immune-based cancer treatments. We're solving some of the biggest challenges, accelerating promising new immunotherapies for patients.
Curious about the latest developments in cancer immunotherapy research? Listen in as leading scientists discuss immune-based treatments across numerous cancer types in our free "Cancer Immunotherapy and You" webinar series.
When the Cancer Research Institute was founded in 1953, we knew then that immune-based treatments would transform cancer medicine. In more than six decades since, we've made numerous groundbreaking discoveries that have given more patients new hope today.
Welcome to the Cancer Research Institute blog. Here we share the latest updates on the field of cancer immunotherapy from CRI, including scientific breakthroughs, news stories, and program announcements. We invite your comments and encourage you to share these stories with your friends.
You can receive notifications of new posts by subscribing to our blog. Just click the RSS icon in the upper right corner.
June 20, 2016
ASCO, CAR T cell therapy
ASCO, CAR T cell therapy, checkpoint-inhibitor, leukemia, lung cancer, lymphoma
AACR, CAR T cell therapy
CAR T cell therapy
Researchers at the University of Pennsylvania publish latest results on an experimental immunotherapy using genetically engineered T cells.
cancer immunotherapy, CAR T cell therapy, emma whitehead, experimental, leukemia, progress
Breakthrough Therapy, CAR T cell therapy, PD-1